Report Description

Forecast Period


Market Size (2023)

USD 175.76 million

CAGR (2024-2029)


Fastest Growing Segment

Liquid Biopsy

Largest Market


Market Size (2029)

USD 269.74 million


Market Overview

Asia-Pacific Multi-Cancer Early Detection Market was valued at USD 175.76 million in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 7.47% through 2029.

The Asia Pacific Multi-Cancer Early Detection Market is a dynamic and rapidly evolving sector within the broader healthcare industry, dedicated to detecting and diagnosing various types of cancer at their earliest stages. This region, encompassing countries such as China, Japan, India, Australia, and many others, is witnessing significant growth in the demand for advanced cancer screening and detection solutions. The market is primarily driven by the increasing prevalence of cancer in the region, coupled with rising awareness and the adoption of early screening measures.

Several key factors contribute to the expansion of the Asia Pacific Multi-Cancer Early Detection Market. Firstly, the growing aging population in many Asian countries has led to a higher cancer incidence, prompting a greater need for effective early detection methods. Secondly, improved healthcare infrastructure and access to diagnostic technologies have made it easier for patients to undergo screening procedures. Thirdly, the rise of precision medicine and advancements in genomics have enabled more accurate and personalized cancer diagnosis, enhancing the effectiveness of early detection methods. Additionally, the increasing investments in healthcare research and development by both public and private sectors are fostering innovation in the field, leading to the introduction of cutting-edge diagnostic tools and techniques.

Key Market Drivers

Rising Cancer Incidence

Rising cancer incidence is a pivotal factor propelling the growth of the Asia Pacific Multi-Cancer Early Detection Market. The region has experienced a significant surge in the number of cancer cases in recent years, making early detection more crucial than ever. The aging population in the Asia Pacific region has led to an increased prevalence of cancer. As individuals grow older, their risk of developing cancer rises, and countries like Japan, South Korea, and China have some of the world's largest and fastest-growing elderly populations. This demographic shift has resulted in a higher demand for cancer screening and early detection services to address the age-associated cancer risk. lifestyle changes and urbanization have brought about shifts in dietary habits, physical activity, and exposure to environmental carcinogens. These factors have contributed to the rising incidence of cancers such as lung, colorectal, and breast cancer. Additionally, the adoption of Western dietary patterns and sedentary lifestyles in some Asian countries has led to a higher prevalence of lifestyle-related cancers. Also, the improved diagnostic techniques and increased awareness have revealed cancers that might have gone undetected in the past. Early screening and advancements in medical imaging have enabled the detection of smaller tumors and precancerous lesions, resulting in higher reported incidence rates.

Aging Population

The aging population in the Asia Pacific region is a significant driving force behind the growth of the Multi-Cancer Early Detection Market. As countries within the Asia Pacific region experience demographic shifts characterized by a rapidly aging population, the demand for advanced and comprehensive cancer screening and early detection services has surged. With life expectancies on the rise and decreasing birth rates, countries like Japan, South Korea, and China are witnessing a profound demographic transformation. The proportion of elderly individuals aged 65 and above is steadily increasing, and they are at a higher risk of developing cancer. This demographic shift has placed an urgent emphasis on the need for early cancer detection and prevention, as the incidence of cancer tends to be higher in older age groups.

Age is a well-established risk factor for various types of cancer. As individuals age, they become more susceptible to cancer due to accumulated genetic mutations and long-term exposure to risk factors. Therefore, the elderly population is more likely to benefit from regular and comprehensive cancer screening to detect malignancies at their earliest, most treatable stages. The burden of cancer in the aging population places substantial pressure on healthcare systems. Detecting cancer at an advanced stage can result in more extensive and expensive treatments, often with less favorable outcomes. This realization has led to a growing awareness of the cost-effectiveness and benefits of investing in early detection, especially for the elderly. In response to these demographic changes, healthcare providers and policymakers in the Asia Pacific region have been prioritizing early cancer screening initiatives tailored to the aging population. This has led to an increased adoption of multi-cancer early detection programs, advanced diagnostic technologies, and comprehensive geriatric oncology care.

Increased Cancer Awareness

The Asia Pacific Multi-Cancer Early Detection Market is experiencing significant growth, propelled in part by the increasing awareness of the importance of cancer screening and early detection among the population. Elevated cancer awareness has emerged as a powerful driver for this market, resulting from various initiatives, education campaigns, and an evolving healthcare landscape within the region. Increased cancer awareness campaigns have played a pivotal role in educating the public about the significance of early detection. Governments, healthcare organizations, and non-governmental organizations have launched various public health campaigns that emphasize the benefits of regular cancer screening and the importance of catching malignancies in their earliest stages. These campaigns are often accompanied by educational materials and outreach efforts that aim to demystify cancer, reduce stigma, and encourage individuals to take charge of their health by undergoing regular screening. The media coverage and the proliferation of information through digital platforms have contributed to a heightened awareness of cancer risks and the importance of early detection. Stories of survival and the latest advancements in cancer diagnostics and treatment are now readily accessible to the public, empowering individuals to seek timely healthcare interventions.

As awareness grows, more individuals are proactively seeking cancer screenings, even in the absence of symptoms or known risk factors. The Asian population is becoming increasingly proactive about their health, understanding that early detection can significantly improve cancer outcomes by enabling more effective treatment options. This proactive approach is translating into a surge in demand for multi-cancer early detection services and screenings. In addition to raising public awareness, healthcare professionals are also more proactive in recommending and offering cancer screening to patients, contributing to the market's expansion. With early detection being emphasized as a vital component of patient care, medical practitioners are increasingly integrated into the efforts to promote cancer awareness and the benefits of early screening.

Download Free Sample Report

Key Market Challenges

High Cost of Advanced Diagnostics

The Asia Pacific Multi-Cancer Early Detection Market faces a formidable obstacle in the form of the high cost of advanced diagnostics. While the region has been witnessing remarkable progress in early cancer detection, affordability remains a significant challenge, impeding the broader adoption of cutting-edge diagnostic technologies and services. Advanced diagnostics, such as liquid biopsies, next-generation sequencing, and AI-driven analyses, have transformed the landscape of cancer screening and early detection. These innovative methods offer higher sensitivity and accuracy, potentially detecting cancers at their earliest, most treatable stages. However, they often come with a hefty price tag, limiting accessibility for a substantial portion of the population.

One of the primary issues is that these advanced diagnostics are often out of reach for individuals in lower-income brackets or those without comprehensive health insurance. As a result, the potential benefits of early cancer detection are not fully realized, and many people remain undiagnosed until their conditions have progressed to more advanced stages, necessitating more aggressive and costly treatments. The high cost of advanced diagnostics can place a significant financial burden on healthcare systems and providers. Governments and healthcare organizations must allocate substantial resources to cover the expenses associated with these diagnostic methods, which may limit their capacity to reach a broader segment of the population. This challenge is particularly pertinent in countries with limited healthcare budgets and resources.

Limited Access to Healthcare Services

Limited access to healthcare services poses a significant challenge to the growth of the Asia Pacific Multi-Cancer Early Detection Market. While this region has made substantial progress in advancing cancer diagnostics, not all individuals have equal access to these life-saving services. Several factors contribute to this limitation and hinder the market's potential. The primary issues is the significant variation in healthcare infrastructure and accessibility across the Asia Pacific region. In urban centers and developed areas, there are typically well-equipped medical facilities with advanced diagnostic capabilities, making early cancer detection more accessible. However, many rural and remote regions lack such infrastructure, leaving residents with limited access to crucial healthcare services.

Geographic disparities in healthcare accessibility are compounded by socioeconomic factors. Individuals in lower-income regions often face greater barriers to healthcare due to financial constraints. High travel costs, out-of-pocket expenses, and the need for time off work can deter people from seeking early detection services, even if they recognize the importance of these screenings. The shortage of skilled healthcare professionals, particularly in remote areas, further exacerbates the problem. Patients in underserved regions may have to travel long distances to access specialized care, and the limited availability of healthcare providers can lead to long waiting times, hindering timely screenings and early cancer detection.

Key Market Trends

Liquid Biopsies

Liquid biopsies are playing a pivotal role in boosting the Asia Pacific Multi-Cancer Early Detection Market. These innovative diagnostic tests have emerged as a revolutionary and transformative trend, significantly improving the landscape of early cancer detection in the region. Liquid biopsies involve the non-invasive analysis of bodily fluids, such as blood, urine, or saliva, to detect cancer-related biomarkers, DNA mutations, and other molecular indicators. Liquid biopsies offer a less invasive and more patient-friendly alternative to traditional tissue biopsies. Many individuals may be hesitant to undergo invasive procedures, such as surgical biopsies, which can lead to discomfort, complications, and longer recovery times. Liquid biopsies, on the other hand, simply require a blood draw or urine sample, making them a more accessible and acceptable option for patients. Liquid biopsies also provide a unique advantage in terms of early cancer detection. These tests can identify cancer-related biomarkers at very early stages of the disease, often before symptoms manifest or tumors become visible on imaging. As a result, they hold great potential for detecting cancer at its most treatable and curable phase, contributing to improved patient outcomes and survival rates. In the Asia Pacific region, where diverse cultural and healthcare disparities can impact healthcare access and patient compliance, the convenience and simplicity of liquid biopsies help overcome these challenges. Patients are more likely to participate in regular cancer screenings when the procedure is minimally invasive and convenient, driving greater adoption of early detection services.

Liquid biopsies are highly versatile, enabling the detection of a wide range of cancer types from a single sample. This multifaceted approach aligns well with the growing trend toward comprehensive multi-cancer early detection, where individuals are screened for multiple types of cancer simultaneously, increasing the likelihood of detecting malignancies early. Ongoing research and development efforts are enhancing the sensitivity and specificity of liquid biopsies, making them even more reliable and accurate for cancer detection. As these tests continue to evolve, they will likely become even more integral to the early detection market in the Asia Pacific region.

Advancements in Genetic Testing

Advancements in genetic testing have emerged as a potent driver behind the growth of the Asia Pacific Multi-Cancer Early Detection Market. The region is witnessing a transformative shift in early cancer detection, with genetic testing technologies playing a central role.  The increasing precision and accessibility of genetic testing have transformed the way healthcare providers diagnose and manage cancer. Genetic testing allows clinicians to identify specific genetic mutations and markers associated with various cancer types. This heightened level of accuracy enables earlier and more precise cancer diagnoses, facilitating timely and targeted treatment plans. The decreasing cost of genetic testing is another significant trend in the Asia Pacific region. As the price of genetic testing technologies and services continues to drop, they become more accessible to a wider segment of the population. This affordability trend aligns with the goal of ensuring equitable access to early cancer detection services, helping reach individuals from diverse socioeconomic backgrounds.

The versatility of genetic testing in detecting a range of cancer types is a key driving force behind its popularity. A single genetic test can provide valuable insights into the predisposition to multiple cancers, making it an efficient and comprehensive screening tool. This aligns well with the multi-cancer early detection approach, where individuals are screened for various cancer types simultaneously. Genetic testing is a cornerstone of personalized medicine, a burgeoning trend in healthcare. By tailoring treatment plans based on an individual's genetic and molecular profile, healthcare providers can optimize the effectiveness of early cancer interventions. This personalized approach increases the likelihood of positive treatment outcomes and is driving the adoption of genetic testing as an integral part of the early detection process.

Segmental Insights

Type Insights

Based on the Type, Liquid Biopsy emerged as the dominant segment in the Asia-Pacific market for Asia-Pacific Multi-Cancer Early Detection Market in 2023. Liquid biopsies are minimally invasive and involve the analysis of bodily fluids such as blood, urine, or saliva. This non-invasive nature makes them highly attractive to patients who may be reluctant to undergo traditional invasive procedures like tissue biopsies. It leads to greater patient compliance and participation in early cancer screening programs. Liquid biopsy technology has seen substantial research and investment, both from the public and private sectors. Ongoing advancements have improved the sensitivity and specificity of these tests. This progress has driven increased adoption and demand in the Asia Pacific Multi-Cancer Early Detection Market.

End-Use Insights

Based on the End-Use, the Diagnostics Laboratories segment emerged as the dominant segment in the Asia-Pacific market for Asia-Pacific Multi-Cancer Early Detection Market in 2023. Diagnostics laboratories are equipped with specialized personnel, including pathologists, clinical laboratory scientists, and technicians, who have the expertise to perform complex cancer screening and early detection tests. This expertise is critical for ensuring accurate and reliable results. Diagnostics laboratories adhere to strict quality control measures, ensuring the reliability and consistency of test results. This is particularly important for early cancer detection, where accurate results are critical for timely intervention and treatment.

Download Free Sample Report

Country Insights

Based on the country, Japan emerged as the dominant Country in the Asia-Pacific Multi-Cancer Early Detection Market in 2023, holding the largest market share. Japan has one of the world's largest and fastest-aging populations, with a high proportion of elderly individuals. As people age, the risk of developing cancer increases, making early detection crucial. This demographic factor has driven the demand for cancer screening services. Japan has a relatively high incidence of cancer, including prevalent cancer types such as gastric cancer, lung cancer, and colorectal cancer. The need for effective early detection is more pronounced in a country with high cancer rates.

Recent Developments

  • In July 2022, Delfi Diagnostics, Inc. secured an investment of USD 225 million to advance the development of a high-performance and affordable Multi-Cancer Early Detection (MCED) test. The company is dedicated to cost reduction initiatives, with the aim of enhancing accessibility to a broader population.
  • In May 2022, Guardant Health introduced "Shield," a Laboratory-Developed Test (LDT) blood assay designed for the early detection of colorectal cancer (CRC) among adults aged 45 and above. The test exhibited an 83% sensitivity in identifying individuals with CRC, while maintaining a consistent 90% specificity for those without advanced neoplasia and for those who received negative colonoscopy results. Additionally, the test displayed a 13% sensitivity in detecting advanced adenomas.
  • In 2023, AnchorDx, a leading diagnostics company, announced a long-term collaboration with DiaCarta, a precision molecular diagnostics company, to develop and globally commercialize cancer screening products. The partnership will leverage proprietary technologies for DNA methylation and mutation detection from both companies. AnchorDx's DNA methylation test, which received FDA Breakthrough Device designation in July 2021, is currently undergoing a registrational clinical trial (NCT05643690), with DiaCarta participating as one of the clinical testing laboratories. This collaboration aims to enhance precision diagnostics with high sensitivity and specificity.

Key Market Players

  • Grail, LLC (Illumina, Inc.)
  • Exact Sciences Corporation
  • Guangzhou AnchorDx Medical Co., Ltd.
  • Guardant Health, Inc. 
  • Burning Rock Biotech Limited
  • Genecast Biotechnology Co., Ltd
  • Singlera Genomics Inc.
  • Laboratory for Advanced Medicine, Inc.
  • MiRXES Pte Ltd.
  • Lucence Health, Inc.

 By Type

By End-Use

By Country

  • Liquid Biopsy
  • Gene Panel
  • LDT
  • Others
  • Hospitals & Clinics
  • Diagnostics Laboratories
  • Others
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
  • Indonesia


Report Scope:

In this report, the Asia-Pacific Multi-Cancer Early Detection Market   has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Asia-Pacific Multi-Cancer Early Detection Market, By Type:

o   Liquid Biopsy

o   Gene Panel

o   LDT

o   Others

  • Asia-Pacific Multi-Cancer Early Detection Market, By End-Use:

o   Hospitals & Clinics

o   Diagnostics Laboratories

o   Others

  • Asia-Pacific Multi-Cancer Early Detection Market, By Country:

o   China

o   Japan

o   India

o   South Korea

o   Australia

o   Thailand

o   Indonesia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Asia-Pacific Multi-Cancer Early Detection Market.

Available Customizations:

Asia-Pacific Multi-Cancer Early Detection Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Asia-Pacific Multi-Cancer Early Detection Market   is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Asia Pacific Multi-Cancer Early Detection Market Outlook

4.1.  Market Size & Forecast

4.1.1.    By Value

4.2.  Market Share & Forecast

4.2.1.    By Type (Liquid Biopsy, Gene Panel, LDT, & Others)

4.2.2.    By End-Use (Hospitals & Clinics, Diagnostics Laboratories, Others)

4.2.3.    By Country

4.2.4.    By Company (2023)

4.3.  Market Map

4.3.1.    By Type

4.3.2.    By End-Use

4.3.3.    By Country

5.    Country Analysis

5.1.  China Multi-Cancer Early Detection Market Outlook

5.1.1.    Market Size & Forecast        By Value

5.1.2.    Market Share & Forecast        By Type        By End Use

5.2.  Japan Multi-Cancer Early Detection Market Outlook

5.2.1.    Market Size & Forecast        By Value

5.2.2.    Market Share & Forecast        By Type        By End Use

5.3.  India Multi-Cancer Early Detection Market Outlook

5.3.1.    Market Size & Forecast        By Value

5.3.2.    Market Share & Forecast        By Type        By End Use

5.4.  South Korea Multi-Cancer Early Detection Market Outlook

5.4.1.    Market Size & Forecast        By Value

5.4.2.    Market Share & Forecast        By Type        By End Use

5.5.  Australia Multi-Cancer Early Detection Market Outlook

5.5.1.    Market Size & Forecast        By Value

5.5.2.    Market Share & Forecast        By Type        By End Use

5.6.  Thailand Multi-Cancer Early Detection Market Outlook

5.6.1.    Market Size & Forecast        By Value

5.6.2.    Market Share & Forecast        By Type        By End Use

5.7.  Indonesia Multi-Cancer Early Detection Market Outlook

5.7.1.    Market Size & Forecast        By Value

5.7.2.    Market Share & Forecast        By Type        By End Use

6.    Market Dynamics

6.1.  Drivers

6.2.  Challenges

7.    Market Trends & Developments

7.1.  Recent Developments

7.2.  Product Launches

7.3.  Mergers & Acquisitions

8.    Asia Pacific Multi-Cancer Early Detection Market: SWOT Analysis

9.    Porter’s Five Forces Analysis

9.1.  Competition in the Industry

9.2.  Potential of New Entrants

9.3.  Power of Suppliers

9.4.  Power of Customers

9.5.  Threat of Substitute Product

10. Competitive Landscape

10.1.       Grail, LLC (Illumina, Inc.)

10.1.1.         Business Overview

10.1.2.          Company Snapshot

10.1.3.          Products & Services

10.1.4.          Financials (In case of listed)

10.1.5.          Recent Developments

10.1.6.          SWOT Analysis

10.2.     Exact Sciences Corporation

10.3.     Guangzhou AnchorDx Medical Co., Ltd.

10.4.     Guardant Health, Inc.

10.5.     Burning Rock Biotech Limited

10.6.     Genecast Biotechnology Co., Ltd

10.7.     Singlera Genomics Inc.

10.8.     Laboratory for Advanced Medicine, Inc.

10.9.     MiRXES Pte Ltd.

10.10.   Lucence Health, Inc.

11. Strategic Recommendations

12. About Us & Disclaimer

Figures and Tables

Frequently asked questions


The market size of the Asia-Pacific Multi-Cancer Early Detection Market was estimated to be USD 175.76 million in 2023.


Grail, LLC (Illumina, Inc.), Exact Sciences Corporation, Guangzhou AnchorDx Medical Co., Ltd., Guardant Health, Inc., Burning Rock Biotech Limited, Genecast Biotechnology Co., Ltd, Singlera Genomics Inc., Laboratory for Advanced Medicine, Inc., MiRXES Pte Ltd., Lucence Health, Inc. are some of the key players operating in the Asia-Pacific Multi-Cancer Early Detection Market.


Healthcare accessibility disparities and the integration of cutting-edge diagnostic technologies within diverse healthcare systems. Additionally, addressing ethical concerns regarding data privacy and patient consent in genetic testing signifies a major challenge for the Asia-Pacific Multi-Cancer Early Detection Market.


Rising incidence of cancer and the region's aging population, emphasizing the need for early detection and intervention. Additionally, increased cancer awareness and the adoption of advanced diagnostic technologies are factors which boost the demand for Asia-Pacific Multi-Cancer Early Detection for monitoring and managing health conditions.


Sakshi Bajaal

Business Consultant
Press Release

Asia Pacific Multi-Cancer Early Detection Market to Grow with a CAGR of 7.47% through 2029

May, 2024

Growing demand for liquid biopsies is expected to drive the Asia-Pacific Multi-Cancer Early Detection Market in the forecast period 2025-2029.